Refractory period (sex) for treating sexual dysfunction. Sildenafil, used in the treatment of erectile dysfunction, was found in one scientific study to have caused "a decreased postejaculatory erectile refractory time (3.2 ± 0.7 vs. 6.4 ± 0.7 minutes)" in men diagnosed with premature ejaculation. It is additionally proposed that the gonadotropin inhibitory hormone (GnIH), which is considered to inhibit the hypothalamic-pituitary-gonadal axis and sexual functions causes refractoriness of the post-ejaculatory refractory period. This hypothesis also supports the increase of oxytocin and prolactin after orgasm in accordance with the previous studies. One alternative theory explains the male refractory period in terms of a peripheral
Corticotropin-releasing hormone receptor 1 II and urocortin III. Variations in the "CRHR1" gene is associated with enhanced response to inhaled corticosteroid therapy in asthma. CRF1 triggers cells to release hormones that are linked to stress and anxiety [original reference missing].Hence CRF1 receptor antagonists are being actively studied as possible treatments for depression and anxiety. Variations in CRHR1 are associated with persistent pulmonary hypertension of the newborn. Corticotropin-releasing hormone receptor 1 has been shown to interact with Corticotropin-releasing hormone and Urocortin. Corticotropin-releasing hormone receptor 1 Corticotropin-releasing hormone receptor 1 (CRHR1) is a protein, also known as CRF, with the latter (CRF) now being the IUPHAR-recommended